A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Trial details
- Registry ID
- NCT02234986
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaNCT02234986 | CASI pharmaceuticals, Inc. | Phase 2 | Completed | 2018-06-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |